• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of gastrointestinal cancer. >Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer
【24h】

Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer

机译：用AfliBercept，5-氟尿嘧啶，白杨蛋白和伊替康用于转移结直肠癌的后逆转脑病综合征

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Posterior reversible encephalopathy syndrome (PRES) is an urgent neurologic condition that is associated with white and gray matter vasogenic edema primarily in parietal and occipital lobes [1]. Clinical features usually involve headache, altered mental status, seizures, and visual disturbances [1]. Although PRES is generally a rare reversible condition, it is increasingly reported in the literature, especially in the setting of cancer patients treated with chemotherapy and antiangiogenic drugs targeting the vascular endothelial growth factor (VEGF) pathway. The combination of aflibercept with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) has been approved for the treatment of patients with metastatic colorectal cancer (mCRC) after the failure of oxaliplatin-based chemotherapy to control the disease [2]. To the best of our knowledge, no cases of PRES related to aflibercept-FOLFIRI can be found in the published literature.
机译：介绍：后逆转脑病综合征（PRES）是一种紧急的神经系统条件，主要是具有白色和灰质血管生成的水肿，主要是位于顶叶和枕骨裂片[1]。 临床特征通常涉及头痛，改变精神状态，癫痫发作和视觉干扰[1]。 虽然PRES通常是一种罕见的可逆条件，但在文献中越来越多地报道，特别是在靶向血管内皮生长因子（VEGF）途径治疗的癌症患者的癌症患者中。 AfliBelcept与5-氟尿嘧啶，白柳素素和伊替替康（Folfiri）的组合已被批准用于在奥沙利铂的化疗失败后治疗转移结直肠癌（MCRC）以控制疾病[2]。 据我们所知，没有与AfliBercept-Folfiri相关的Prans的案件可以在公开的文献中找到。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号